Investors who lost money on Intellia Therapeutics, Inc.(NTLA) should contact The Gross Law Firm about pending Class Action - NTLA

Core Viewpoint - Intellia Therapeutics is facing a class action lawsuit due to alleged misleading statements regarding its NTLA-3001 program for treating alpha-1 antitrypsin deficiency-associated lung disease, leading to a significant drop in stock price after the company announced a halt in research and workforce reduction [3][4]. Group 1: Company Overview - Intellia Therapeutics, Inc. (NASDAQ: NTLA) is involved in developing treatments for genetic diseases, with a focus on its NTLA-3001 program [3]. - The company had previously expressed confidence in its timeline for the NTLA-3001 study, expecting to dose the first patient in the second half of 2024 [3]. Group 2: Allegations and Developments - The lawsuit alleges that Intellia failed to disclose that demand for viral-based editing was declining as non-viral methods gained preference in the scientific community, making NTLA-3001 an inefficient program [3]. - On January 9, 2025, Intellia announced a reorganization, halting all NTLA-3001 research and reducing its workforce by 27% in 2025, which led to a stock price drop from $12.02 on January 8, 2025, to $10.20 on January 10, 2025 [3][4]. Group 3: Class Action Details - Shareholders who purchased NTLA shares between July 30, 2024, and January 8, 2025, are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4].